CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

CiclesonideWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug525 Follow up Wiki 0.71
drug1016 Placebo Wiki 0.08

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D001927 Brain Diseases NIH 0.58
D016638 Critical Illness NIH 0.20

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0001298 Encephalopathy HPO 0.71

There is one clinical trial.

Clinical Trials

1 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ciclesonide Metered-Dose Inhaler in Non-hospitalized Patients 12 Years of Age and Older With Symptomatic COVID-19 Infection

The purpose of this study is to assess the safety and efficacy of Alvesco (ciclesonide) Inhalation Aerosol in non hospitalized patients with symptomatic COVID-19 infection in a multicenter, randomized, double-blind, placebo controlled study

NCT04377711 COVID-19 Drug: Ciclesonide Drug: Placebo

Primary Outcomes

Measure: Percentage of patients hospital admission or death by day 30

Time: Day 30

Secondary Outcomes

Measure: All-cause mortality by day 30

Time: Day 30

Measure: COVID-19-related mortality by day 30

Time: Day 30

Measure: Percentage of patients with subsequent emergency department visit or hospital admission for reasons attributable to COVID 19 by day 30

Time: Day 30

Measure: Time to hospital admission or death

Time: Day 30

Measure: Time to alleviation of COVID-19-related symptoms of cough, dyspnea, chills, and feeling feverish, defined as symptom-free for a continuous period of more than 24 hours (ie, > 3 AM/PM assessments)

Time: Day 30

Measure: Change from baseline in oxygen saturation levels

Time: Day 30

Measure: Change from baseline in COVID-19 viral load in nasopharyngel sample nasal secretions at day 30

Time: Day 30

Measure: Safety will be assessed based on adverse events.

Time: Day 60

No related HPO nodes (Using clinical trials)